Luca Cindolo1, Clara Natoli2, Cosimo De Nunzio3, Michele De Tursi2, Maurizio Valeriani4, Silvana Giacinti5, Salvatore Micali6, Mino Rizzo6, Giampaolo Bianchi6, Eugenio Martorana6, Marcello Scarcia7, Giuseppe Mario Ludovico7, Pierluigi Bove8, Anastasia Laudisi9, Oscar Selvaggio10, Giuseppe Carrieri10, Maida Bada1, Pietro Castellan1, Luca Topazio11, Stefano Boccasile12, Pasquale Ditonno12, Paolo Chiodini13, Luigi Schips1. 1. Department of Urology, ASL Abruzzo 2, Chieti, Italy. 2. Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy. 3. Department of Urology, "Sant'Andrea" Hospital, "Sapienza University", Roma, Italy. 4. Radiation Therapy Unit, "Sant'Andrea" Hospital, "Sapienza University", Roma, Italy. 5. Oncology Unit, "Sant'Andrea" Hospital, "Sapienza University", Roma, Italy. 6. Department of Urology, University of Modena and Reggio Emilia, Baggiovara Hospital, Baggiovara, Italy. 7. Ente Ecclesiastico Ospedale "F. Miulli", Acquaviva delle Fonti, Italy. 8. Department of Experimental Medicine and Surgery, Azienda Policlinico Tor Vergata, Roma, Italy. 9. UOSD of Medical Oncology, Azienda Policlinico Tor Vergata, Roma, Italy. 10. Department of Urology, University of Foggia, Foggia, Italy. 11. Department of Experimental Medicine and Surgery, Azienda Policlinico Tor Vergata, Roma, Italy. Electronic address: lucatpz@hotmail.it. 12. Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. 13. Medical Statistics Unit, Second University of Naples, Naples, Italy.
Abstract
INTRODUCTION: Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA. MATERIALS AND METHODS: This was a retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death, or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. Eastern Cooperative Oncology Group score, pain symptoms, treatment-related toxicity, prostate-specific antigen (PSA), and overall and progression-free survival were recorded. Satisfaction with treatment was investigated at 6 months by means of a 4-point arbitrary scale. RESULTS: One-hundred twenty-eight patients were enrolled. Patients' satisfaction with treatment was "greatly improved" in 36.1% of patients and "improved" in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (P < .05), lower PSA levels at 12 weeks (P = .080), and less pain symptoms and lower Brief Pain Inventory scores (P = .001). Satisfaction with treatment was significantly correlated with baseline PSA level (P = .018), presence of pain (P = .007), duration of androgen deprivation therapy >12 months (P = .025), and number of hormonal manipulations (P = .051). Progression-free survival significantly correlated with patient satisfaction (P < .001). CONCLUSION: AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PROs. Patient's satisfaction is a predictor of progression-free survival.
INTRODUCTION:Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA. MATERIALS AND METHODS: This was a retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death, or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. Eastern Cooperative Oncology Group score, pain symptoms, treatment-related toxicity, prostate-specific antigen (PSA), and overall and progression-free survival were recorded. Satisfaction with treatment was investigated at 6 months by means of a 4-point arbitrary scale. RESULTS: One-hundred twenty-eight patients were enrolled. Patients' satisfaction with treatment was "greatly improved" in 36.1% of patients and "improved" in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (P < .05), lower PSA levels at 12 weeks (P = .080), and less pain symptoms and lower Brief Pain Inventory scores (P = .001). Satisfaction with treatment was significantly correlated with baseline PSA level (P = .018), presence of pain (P = .007), duration of androgen deprivation therapy >12 months (P = .025), and number of hormonal manipulations (P = .051). Progression-free survival significantly correlated with patient satisfaction (P < .001). CONCLUSION: AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PROs. Patient's satisfaction is a predictor of progression-free survival.
Authors: Luca Cindolo; Clara Natoli; Cosimo De Nunzio; Michele De Tursi; Maurizio Valeriani; Silvana Giacinti; Salvatore Micali; Mino Rizzo; Giampaolo Bianchi; Eugenio Martorana; Marcello Scarcia; Giuseppe Mario Ludovico; Pierluigi Bove; Anastasia Laudisi; Oscar Selvaggio; Giuseppe Carrieri; Maida Bada; Pietro Castellan; Stefano Boccasile; Pasquale Ditonno; Paolo Chiodini; Paolo Verze; Vincenzo Mirone; Luigi Schips Journal: BMC Cancer Date: 2017-11-10 Impact factor: 4.430
Authors: Cecília M Alvim; André Mansinho; Rita S Paiva; Raquel Brás; Patrícia M Semedo; Soraia Lobo-Martins; Carolina B da Ponte; Daniela Macedo; Leonor Ribeiro; José P Dos Reis; Isabel Fernandes; Luís Costa Journal: Future Sci OA Date: 2019-12-12